pd 169316 has been researched along with Memory Disorders in 1 studies
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor
Memory Disorders: Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashabi, G | 1 |
| Ramin, M | 1 |
| Azizi, P | 1 |
| Taslimi, Z | 1 |
| Alamdary, SZ | 1 |
| Haghparast, A | 1 |
| Ansari, N | 1 |
| Motamedi, F | 1 |
| Khodagholi, F | 1 |
1 other study available for pd 169316 and Memory Disorders
| Article | Year |
|---|---|
ERK and p38 inhibitors attenuate memory deficits and increase CREB phosphorylation and PGC-1α levels in Aβ-injected rats.
Topics: Amyloid beta-Peptides; Animals; Blotting, Western; Butadienes; CA1 Region, Hippocampal; Cyclic AMP R | 2012 |